Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13877018 | 0.86 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2316240 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2318411 | 0.81 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL11089109 | 0.79 | TDP1 (0.69) | MAPK14AKR1B1MAOB | |
| SCHEMBL2315002 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4602012 | 0.76 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL4222228 | 0.76 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2313116 | 0.76 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL2316370 | 0.76 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4040669 | 0.76 | CES1 (0.61) | MAPK14AKR1B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | claimed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | claimed |
| EP-2349964-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | c-a-i-r biosciences GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| EP-2206534-A1 | Dibenzocycloheptanone derivatives und pharmaceutical agents containing these compounds | c-a-i-r biosciences GmbH (DE) | 2010-07-14 | — | — | EP | claimed |
| WO-2010040843-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2010-04-15 | — | — | WO | claimed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2349964-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | c-a-i-r biosciences GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2206534-A1 | Dibenzocycloheptanone derivatives und pharmaceutical agents containing these compounds | c-a-i-r biosciences GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010040843-A2 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885AKR1B1 4016/4885MAPK13 303/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885AKR1B1 3901/4885MAPK13 286/4885 |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885AKR1B1 4071/4885MAPK13 304/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885AKR1B1 4016/4885MAPK13 303/4885 |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | IL1B, NFKBIA, IL1R1 | MAPK14 2812/4885AKR1B1 141/4885MAPK13 2654/4885 |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885AKR1B1 4016/4885MAPK13 303/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885AKR1B1 4016/4885MAPK13 303/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885AKR1B1 4016/4885MAPK13 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.